Dominant Negative Form of Signal-regulatory Protein-alpha (SIRPalpha /SHPS-1) Inhibits Tumor Necrosis Factor-mediated Apoptosis by Activation of NF-kappa B*

Nickolay NeznanovDagger §, Lubov NeznanovaDagger , Roman V. Kondratov, Ludmila Burdelya, Eugene S. Kandel, Donald M. O'Rourke||, Axel Ullrich**, and Andrei V. Gudkov

From the Dagger  Department of Virology and  Molecular Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, the || Departments of Neurosurgery and Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, and the ** Department of Molecular Biology, Max-Planck-Institute fur Biochemie, 82152 Martinsried, Germany

Received for publication, October 18, 2002, and in revised form, November 22, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Genetic suppressor element (GSE) methodology was applied to identify new genes controlling cell response to tumor necrosis factor (TNF). A retroviral library of randomly fragmented normalized cDNA from mouse fibroblasts was screened for GSEs capable of protecting NIH3T3 cells from TNF-induced apoptosis. The most abundant among isolated GSEs represented a fragment of cDNA encoding the C-terminal cytoplasmic region of the immunoglobulin family inhibitory receptor, SHPS-1 (mouse homologue of human SIRPalpha ). Ectopic expression of this fragment (both from human and mouse versions) increased the NF-kappa B-dependent transcription in three cell lines tested; this effect could be reduced by the expression of full-length SIRPalpha , suggesting that the isolated GSE acts through a dominant negative mechanism. GSE-mediated activation of NF-kappa B depended on the presence of serum, was abrogated by wortmannin, and was associated with phosphorylation of PKB/Akt, suggesting that Akt mediates it. These data indicate that SIRPalpha /SHPS-1 is involved in negative regulation of NF-kappa B signaling.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Tumor necrosis factor (TNF)1 is involved in many disease-related processes in the organism, including inflammation, anti-viral, anti-cancer, and immune responses (1). In combination with inhibitors of transcription or translation, TNF can induce apoptosis in sensitive cells in cell culture. This apoptosis is initiated by binding TNF to its plasma membrane receptors, which belong to the death receptor family. After death receptors have been triggered, the adaptor molecules, including FADD and TRADD and the receptor proximal caspase 8, are engaged to form a death-inducing signaling complex (DISC). Upon recruitment to the DISC, caspase 8 becomes activated and mediates cleavage of procaspase 3, starting a chain of events that results in apoptotic death (2).

The key role played by TNF pathway in many pathological processes indicates the importance of its control by pharmacological approaches (3). Rational design of such approaches requires identification of cellular factors involved in regulation of TNF-mediated death, some of which have been already determined. Pro-apoptotic function of TNF can be counterbalanced by simultaneous activation of anti-apoptotic NF-kappa B pathway, which can effectively prevent initiation of a death cascade through transcriptional induction of a number of apoptosis inhibitors (4). NF-kappa B is functionally linked to Akt signaling pathway, an important sensor of environmental conditions (i.e. availability of growth factors) strongly contributing to the "to die or not to die" decision. It can greatly reduce suicidal intentions of the cell in the presence of growth factors and other ligands specific to healthy growth conditions and natural microenvironments (5).

The signaling from phosphoinositide 3-kinase (PI3K) to the protein kinase Akt is an evolutionary conserved ancient pathway that controls organism life span in invertebrates and cell survival and proliferation in mammals (6). Many cell-surface receptors induce production of second messengers, like phosphatidylinositol 3,4,5-trisphosphate (PIP3), that convey signals to the cytoplasm from the cell surface. PIP3 signals activate 3-phosphoinositide-dependent protein kinase-1, which in turn activates the kinase Akt, also known as protein kinase B. Akt promotes cell survival and opposes apoptosis by a variety of routes, including the activation of NF-kappa B through phosphorylation of inhibitory kappa B kinase (7).

Both NF-kappa B and Akt signaling are integrated into a network of cellular regulatory pathways through numerous components, only some of which have been identified. To determine new regulators of TNF apoptotic pathway, we used the genetic suppressor elements (GSE) approach, a functional genetic methodology designed for cloning genes associated with recessive phenotypes (8, 9). It was successfully used before for identification of genes involved in negative control of cell growth, including drug sensitivity and candidate tumor suppressor genes (8, 10, 11, 12). GSEs act by encoding either inhibitory antisense RNA or dominant negative truncated proteins. They are isolated from expression libraries of randomly fragmented cDNAs by functional selection. GSEs suppressing TNF-induced apoptosis would likely be derived from and act against the genes that could be important for TNF-mediated death and therefore can be used for identification and cloning.

Among genetic elements protecting cells from TNF-specific apoptosis, we isolated a GSE that encoded the cytoplasmic part of the inhibitory receptor SHPS1 (the mouse homologue of human SIRPalpha ) (13, 14), known to bind and activate the SH2 domain containing protein tyrosine phosphatases, SHP-1 and SHP-2, and inositol phosphatase, SHIP (15). These phosphatases are known to be involved in cytoplasmic signaling downstream of a variety of cell surface receptors and to be capable of modulating NF-kappa B (16). In fact, ectopic expression of SHPS-1/SIRPalpha -derived GSE resulted in a strong Akt-dependent activation of NF-kappa B that is likely to be responsible for the GSE-mediated TNF resistance. Overexpression of full-length SHPS-1/SIRPalpha protein caused effects opposite to that of the GSE, indicating that the isolated element acts through a dominant negative mechanism. These observations suggest that SHPS-1/SIRPalpha is a natural negative regulator of NF-kappa B signaling, presumably involved in the control of cell response to a variety of stimuli acting through this important pathway.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cells, Transfection, and Retrovirus Infection-- A4 (p53-deficient mouse embryo fibroblasts transformed by E1a+ras), NIH3T3, NIH3T3-derived amphotropic and ecotropic packaging cells GP+E86 and GP+envAm12 (17), and HeLa, 293, and Ecopack (Clontech) cell lines were cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal calf serum. The transfections of NIH3T3, HeLa, 293, and Ecopack cells were conducted with LipofectAMINE PLUS reagent (Invitrogen) according to the provider's protocols. Retroviral infection was accomplished by transferring virus-containing medium supplemented with 4 µg/ml polybrene (Sigma).

Plasmids and Libraries-- The preparation of the GSE library from poly(A)+ RNA of NIH3T3 cells was previously described (8). The library was made in pLNCX retroviral expression vector (18) and contains 3 × 107 independent clones expressing random 150-400-bp fragments of normalized cDNA. Synthetic adapters providing initiator codons upstream of the insert in all reading frames flank each fragment. GSEs were isolated from selected cells by RT-PCR and recloned into pCR2.1 vector (Invitrogen) for sequencing. GSE2-1 and GSESIRP, representing the entire C-terminal part of SHSP1/SIRPalpha , were synthesized by RT-PCR from total RNA of NIH3T3 and HeLa cells, respectively, using 5'-GAATTCTGCAACCATGGAACAG-3' sense and 5'-GGATCCATCACTTCCTCTGGACCT-3' antisense primers for GSE2-1 and 5'-GAATTCTCGCAACCATGGGACAG-3' sense and 5'-GGATCCATCACTTCCTCGGGACCTG-3' antisense primers for GSESIRP. The targeted mutagenesis, which converted tyrosines to phenylalanines codons, was done by PCR. For functional testing, all the generated fragments were cloned into pLXSN retroviral expression vector, also conferring G418 resistance. The complete coding region of full-length SIRPalpha cDNA was recloned from Expressed Sequence Tag accession numbers AI357578 and BE514786 into pcDNA3 expression vector (Invitrogen). cDNA for the S32A/S36A mutant of IkBalpha (super-repressor mutant form of IkB) in pBabePuro expression vector was a gift from Dr. S. S. Makarov (19).

GSE Library Screening for TNF Resistance-conferring Elements-- 2 × 106 ECOPACK retrovirus packaging cells were transfected with 3 µg of GSE library or insert-free pLNCX plasmid (control) by standard LipofectAMINE PLUS reagent protocol. The virus-containing medium from transfected cells was transferred on 2 × 106 NIH3T3 amphotropic packaging cells followed by G418 selection. 5 × 105 G418-resistant NIH3T3 amphotropic cells per plate were treated with TNF (0.01 ng/ml) in the presence of 1 µg/ml cycloheximide (CHI). Virus-containing medium from the cells that survived TNF treatment (8-10% of the infected population) was transferred to 2 × 106 NIH3T3 ecotropic packaging cells that were subjected to the second round of selection. We alternated amphotropic and ecotropic packaging cells in this screening to improve the efficiency of infection with retroviruses (ecotropic packaging cells are resistant to infection with ecotropic virus, as amphotropic packaging cells are to amphotropic virus). The last round of selection was done on NIH3T3 cells that are more sensitive to TNF than packaging cell lines. After 3-4 rounds of selection, a significant increase in the proportion of TNF-resistant cells was observed in the population infected by the library-carrying but not in control insert-free virus. Library inserts from NIH3T3 cells surviving after TNF/CHI treatment were isolated by RT-PCR, using two subsequent PCR reactions with two sets of nested primers to increase specificity of the GSE rescue. The first round of PCR was done with primers specific to the pLNCX vector sequences flanking the inserts, 5'-CCAAGCTTTGTTTACATCGATG-3' (sense) and 5'-ATGGCGTTAACTTAAGCTGCTT-3' (antisense), followed with the second PCR that involved the sense-oriented strand of the adapter 5'-AATCATCGATGGATGGATGG-3'.

NF-kappa B Luciferase Reporter Assay-- The efficiency of NF-kappa B transcriptional activity was estimated using reporter plasmid containing minimal promoter of the c-fos gene (20) combined with two oligonucleotides corresponding to NF-kappa B-binding sites from human immune deficiency virus long terminal repeat (21). The efficiency of transfection in luciferase assay experiments was estimated by beta -galactosidase expression from a co-transfected pcDNA3-lacZ plasmid, and the results of luciferase assays were normalized accordingly.

Western Immunoblotting-- Total protein extracts from 2 × 106 293 cells expressing full-length SIRPalpha , GSE2-1, GSESIRP, and GSE1FSIRP proteins in 50 µl of RIPA buffer (150 mM NaCl, 1% SDS, 10 mM Tris, pH8.0, 1% sodium deoxycholate, 1% Nonidet P-40) with the protease inhibitor mixture (SIGMA) were separated by electrophoresis in 4-20% precast polyacrylamide gels with SDS (Novex) and transferred to nylon polyvinylidene difluoride membranes Hybond P (Amersham Biosciences). Immune complexes were visualized by enhanced chemiluminescence (ECL, Amersham Biosciences) after incubation with primary rabbit polyclonal anti-SIRPalpha /SHPS-1 antibodies (Upstate Biotechnology). For Akt phosphorylation analysis, 2 × 106 293 cells were lysed in RIPA buffer containing 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, and 125 µM sodium ortovanadate (inhibitor of protein phosphatases) (all from Sigma). Protein concentrations in supernatants were determined with the Bio-Rad protein assay kit. 40 µg of each protein sample were subjected to SDS-PAGE electrophoresis 4-20% and transferred to polyvinylidene difluoride membrane (Amersham Biosciences). The membrane was incubated with rabbit polyclonal phospho-Akt (Ser473) primary antibodies (Cell Signaling Technology) or, for quantitation, goat polyclonal anti-actin antibodies (Santa Cruz). Horseradish peroxidase-conjugated secondary anti-rabbit antibodies were purchased from Cell Signaling Technology, and anti-goat antibodies were purchased from Santa Cruz. After extensive washing in phosphate-buffered saline, the membrane was developed with ECL (PerkinElmer Life Sciences). Quantitation of the data was performed using Quantity One software from Bio-Rad.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Functional Selection of GSEs Protecting from TNF-induced Apoptosis-- The scheme explaining the screening of the retroviral GSE library of normalized fragmented cDNA of NIH3T3 is shown in Fig. 1A and is fully addressed under "Experimental Procedures." 2 × 106 library-producing NIH3T3-derived packaging cells sensitive to TNF were treated with TNF in the presence of inhibitor of translation CHI under conditions that resulted in killing >90% of the cells. After expansion of the surviving population, virus produced by these cells (and presumably enriched in clones conferring TNF resistance) was transferred to another type of packaging cells permissive for the infection with the isolated virus, and treatment was repeated. Up to four rounds of selection were applied before virus transfer became evidently capable of conferring TNF resistance to NIH3T3 cells as compared with control vector virus subjected to the same selection procedure (20-25% versus 2-3% of TNF-resistant cells among infected NIH3T3). At this stage, selected GSE inserts isolated by RT-PCR were recloned and sequenced. 40% of all rescued GSE clones in one of the lines of screening contained the same sequence, named GSE2. The proportion of this sequence, undetectable in the original GSE population before TNF selection, gradually increased with each next round of selection, as determined by Southern blot hybridization of PCR products of the mixture of cDNA GSE inserts isolated by PCR at different stages of screening (Fig. 1B). This GSE was subjected to a more detailed analysis.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 1.   Isolation of SHPS-1 fragment conferring resistance to TNF. A, scheme of selection of GSEs protecting against TNF-induced apoptosis. B, enrichment of GSE2-expressing cells during selection against TNF-specific apoptosis. The results of Southern hybridization of RT-PCR products generated using primers specific for LNCX vector sequences flanking the library inserts. 1 µg of total RNA from cells infected with GSE library before TNF selection (0) and after 1, 2, or 3 rounds of selection (lanes 1-3) was used for RT-PCR. C, the amino acid sequence of SHPS-1 (in bold) aligned with the GSEs isolated or generated. The cytoplasmic part of the protein is underlined. Asterisks mark the homologous amino acids between mouse and human proteins. Bold letter in GSESIRP marks the tyrosine substitution with phenylalanine in GSE1FSIRP.

Sequence analysis of GSE2 showed that it represents a sense-oriented fragment of cDNA encoding a cytoplasmic part of a known protein, inhibitory receptor SHPS-1 (accession number NM007547). (The human homologue is named signal regulatory protein alpha  or SIRPalpha ). The SHPS-1/SIRPalpha corresponding open reading frame in GSE2 starts from the second initiator codon of the adapter and encodes 99 amino acid residues from the cytoplasmic part of SHPS-1, with the exception of the very C-terminal part that includes the last C-terminal tyrosine site for phosphorylation (Fig. 1C). Structurally, SHPS-1/SIRPalpha belongs to the immunoglobulin family of receptors. When activated by Src-mediated phosphorylation of a specific tyrosine residue, SHPS-1/SIRPalpha can affect the signaling pathways between epidermal growth factor receptor and PI3K (22) through binding the SH2-domain containing phosphotyrosine phosphatases SHP-1 and SHP-2. No connection has been reported so far between SHPS-1/SIRPalpha and TNF-dependent apoptosis.

Cytoplasmic Domain of SHPS-1/SIRPalpha Protects Mouse Fibroblasts from TNF-induced Apoptosis-- GSE2 in the selected clone was in sense orientation and could potentially express the majority of the cytoplasmic part of SHPS-1/SIRPalpha if translated from the second ATG codon of the adapter. However, two other start codons in alternative frames could, in principle, initiate the translation of SHPS-1/SIRPalpha -unrelated peptides, which could be responsible for the observed effect. To rule out this possibility, we modified the GSE2 sequence to eliminate two alternative initiator codons and cloned it into another retroviral vector (pLXSN) under the control of the long terminal repeat promoter. In parallel, we synthesized by RT-PCR and cloned into the same vector the fragment of SHPS-1/SIRPalpha cDNA that encodes the entire C-terminal region of the protein, supplying it with the initiator ATG codon (GSE2-1) (Fig. 1C).

All these constructs, including insert-free vector, were converted into retroviruses by transfection of packaging cells and transduced into two mouse cell lines (NIH3T3 and A4) that were then tested for TNF resistance. Only GSE2 and GSE2-1 efficiently protected the infected cells from TNF-specific apoptosis (Fig. 2). Cells infected with GSE2-1 in antisense orientation showed the same sensitivity to TNF as the cells infected with empty pLXSN vector and the original cells. No difference in the potency of TNF protection was found between GSE2 and GSE2-1, indicating that the last tyrosine of SHPS-1/SIRPalpha , which was reported to be important for SHPS-1/SIRPalpha function (23), is dispensable in the GSE activity. Thus, biological activity of the isolated GSE is indeed the function of the C-terminal fragment of SHPS-1/SIRPalpha protein expression.


View larger version (73K):
[in this window]
[in a new window]
 
Fig. 2.   Ectopic expression of GSE2 protects cells from TNF-induced apoptosis. A, NIH3T3 cells were infected with "empty" LXSN retrovirus and with retrovirus expressing GSE2 and selected for G418 resistance. The resulting populations were treated for 8 h with TNF in the presence of CHI (TNF/CHI) and stained with DAPI (4,6-diamidino-2-phenylindole), which reveals apoptotic cells by bright spots of condensed chromatin. B, relative survival of NIH3T3 cells after 8 h of TNF/CHI treatment. The cells remaining on the plates after treatment were fixed with formaldehyde and stained with methylene blue. The dye was extracted with 0.1 M HCl and measured at 560 nm. The average data of two experiments are presented. u/t, untreated cells. C, GSE2-1, a modified version of GSE2, also protects mouse cells from TNF. Mouse fibroblast cells, A4, were infected with retrovirus expressing GSE2-1 in sense (1, 2) and antisense orientation (3, 4). The transduced population was either untreated (u/t) (panels 1 and 3) or treated with TNF/CHI for 10 h (panels 2 and 4), followed by a 24-hour incubation in TNF/CHI-free medium. D, quantitation of the results of the experiment shown in panel C using methylene blue assay. Only expression of sense-oriented GSE2-1 protected cells against TNF-induced apoptosis. TNF sensitivity of GSE2-1AS (antisense orientation)-expressing cells was at the level of the population transduced with insert-free vector.

Cytoplasmic Domain of SHPS-1/SIRPalpha Can Activate NF- kappa B-- TNF is known to stimulate activation of NF-kappa B possessing pro-inflammatory and anti-apoptotic functions (24, 25). NF-kappa B activation by TNF and platelet-derived growth factor requires Akt serine-threonine kinase (26, 27). SIRPalpha was reported to have negative regulatory effects on cellular responses to growth factors (13) and to inhibit EGF-induced PI3K activation (22). Because SIRPalpha affects the PI3K/Akt pathway, we speculated that it can modulate TNF signaling through Akt-dependent NF-kappa B activation. To test this hypothesis we analyzed NF-kappa B activity in the cells overexpressing GSE2-1 and full-length SIRPalpha , using specific reporter constructs expressing NF-kappa B-dependent luciferase. The results of these experiments are presented in Fig. 3A. They show that GSE2-1 stimulates basal activity of NF-kappa B up to 8 times. At the same time, overexpression of the full-length SIRPalpha protein had the effect opposite to that of the GSE, causing a decrease in the activity of NF-kappa B (Fig. 3A). Neither construct had any effect on the expression of luciferase reporter with minimal promoter (data not shown).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3.   Ectopic expression of GSE2-1 and full-length SIRPalpha has opposite effects on transcriptional activity of NF-kappa B. A, HeLa, NIH3T3, and 293 cells were cotransfected with the combination of 50 ng of NF-kappa B-responsive luciferase reporter construct and 1 µg of empty vector (control), or 1 µg of GSE2-1-expressing plasmid, or 1 µg of full-length SIRPalpha expression plasmid, and 50 ng of beta -galactosidase-expressing plasmid as a control for efficiency of transfection. Data represent luciferase activity relative to the level of control cells after normalization to the efficiency of transfection. The average data of four experiments are presented. B, the super-repressor mutated form of Ikappa B (SRIkappa B) abolishes TNF- and GSE2-1-dependent activation of NF-kappa B. 293 cells were transfected as described in the legend to panel A. Cells were lysed 4 h after treatment with 0.01 ng/ml TNF followed by luciferase detection in the lysate. 500 ng of SRIkappa B expression vector were used for transfection. Bars represent average results of two experiments. C, detection of truncated and full-length SIRPalpha proteins by Western immunoblotting. 293 cells were cotransfected with 1 µg of plasmids expressing corresponding GSE or full-length SIRPalpha and 50 ng of green fluorescence protein-expressing plasmid (control of transfection efficiency). Total protein extracts were made in 50 µl of RIPA solution. 10 µl of protein extract was used for Western blotting analysis. Lane 1, GSESIRP; lane 2, GSE2-1; lane 3, GSE1FSIRP; lane 4, SIRPalpha ; lane 5, untransfected cells extract. Notice that the expression level of exogenous full-length SIRPalpha always exceeded that of the endogenous gene, whereas the expression of the truncated protein was close to the endogenous gene. The mobility of GSE2-1 differed from GSESIRP and GSE1FSIRP because GSE2-1 is the fragment of the mouse homologue of human SIRPalpha .

The mutated form of Ikappa B known as "super-repressor," which can effectively inhibit NF-kappa B transcriptional activity at the step of translocation of NF-kappa B to the nucleus (19), has often been used to prove the NF-kappa B-specificity of the studied effects (19, 27). We expressed the super-repressor form of Ikappa B in combination with GSE2-1 and found that it can neutralize the NF-kappa B-activating effect of the GSE as well as the activation of NF-kappa B by TNF (Fig. 3B).

The activity of full-length SIRPalpha depends on the phosphorylation of tyrosine residues in the cytoplasmic part of the protein by Src tyrosine kinase (13); only the phosphorylated form of SIRPalpha can bind SHP-1 and -2 protein phosphatases (13, 22). We checked whether this phosphorylation is crucial to the NF-kappa B-inducing activity of the cytoplasmic fragment of SHPS-1/SIRPalpha . In these experiments we used the construct expressing the human homologue, named GSESIRP, of mouse GSE2-1 that has a similar biological effect on NF-kappa B. Substitution of tyrosine for phenylalanine within the consensus of immunoreceptor tyrosine-based inhibitory motif (ITIM) (V/IXYXXV/L) decreased the ability of GSE1FSIRP to activate NF-kappa B in all cell lines tested (Fig. 4). The mutation form of GSE with three tyrosines changed for phenylalanines completely lost the ability to activate NF-kappa B (data not shown). It is noteworthy that all the versions of GSE2 and GSESIRP were expressed in our experiments at a level comparable with those of endogenous SHPS-1/SIRPalpha , whereas ectopic expression of full-length constructs resulted in high levels of SHPS-1/SIRPalpha that significantly exceeded the level of endogenous protein (Fig. 3C).


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 4.   The substitution of ITIM tyrosine for phenylalanine (GSE1FSIRP) decreases the ability of GSE to activate NF-kappa B-specific transcription. HeLa and NIH3T3 cells were transfected and analyzed as described in the legend to Fig. 3A. All data represent the average of two experiments.

The Cytoplasmic Domain of SHPS-1/SIRPalpha Is Likely to Act through a Dominant Negative Mechanism-- Expression of the cytoplasmic portion of SHPS-1/SIRPalpha protected cells against TNF-induced apoptosis, presumably through its ability to activate NF-kappa B. On the contrary, ectopic expression of full-length SHPS-1/SIRPalpha makes cells more sensitive to TNF-stimulated apoptosis (Fig. 5A). This effect was stronger in HeLa than in NIH3T3 cells because of higher sensitivity of NIH3T3 cells to TNF-specific apoptosis (Fig. 5A). Consistently, full-length SHPS-1/SIRPalpha caused an inhibitory effect on NF-kappa B activity (Fig. 3A). These observations suggested that the cytoplasmic portion of SHPS-1/SIRPalpha acts as a dominant negative mutant. In fact, cotransfection of cells with different ratios of plasmids encoding truncated and full-length versions of SHPS-1/SIRPalpha showed that the excess of full-length SHPS-1/SIRPalpha decreased the ability of GSE2-1 to activate NF-kappa B (Fig. 5B).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 5.   GSE2-1 acts as a dominant negative form of SIRPalpha . A, overexpression of full-length SIRPalpha sensitizes cells to TNF. The indicated cells were treated with TNF (0.01 ng/ml) and CHI (1 µg/ml for NIH3T3 and 5 µg/ml for HeLa) for 8 h. Remaining cells were quantitated by methylene blue assay. Data represent the average of three experiments. B, overexpression of full-length SIRPalpha decreases activation of NF-kappa B by GSE2-1. Because of the high level of SIRPalpha expression (see Fig. 3C), we used 50 and 100 ng of SIRPalpha -expressing plasmid in cotransfection with 1 µg of GSE2-1-expressing vector to reach 5-10-fold excess of SIRPalpha over GSE2-1. In control transfection, 1 µg of pLXSN was used instead of 1 µg of GSE2-1-expressing vector. Column 1, control 293 cells; column 2, GSE2-1; column 3, SIRPalpha /GSE2-1, 5:1; column 4, pcDNA3/GSE2-1, 5:1; column 5, SIRPalpha /GSE2-1, 10:1; column 6, pcDNA3/GSE2-1, 10:1. The data represent the average of two experiments.

Activation of NF-kappa B by the Cytoplasmic Portion of SHPS-1/SIRPalpha is Akt-dependent-- GSE2-1 did not stimulate NF-kappa B-dependent transcription in serum-free medium in NIH3T3 cells (Fig. 6A), suggesting the involvement of PI3K/Akt signaling in the GSE activity. We used wortmannin, an inhibitor of PI3K kinase (26), to analyze whether GSE2-1 indeed needs PI3K/Akt to activate NF-kappa B. Cells were transfected and maintained in serum-free medium overnight. An additional 10% of fetal calf serum activated NF-kappa B-mediated transcription of the reporter, and the expression of GSE2-1 had an additive effect (Fig. 6A). Wortmannin completely inhibited NF-kappa B-mediated transcription caused both by addition of growth factors and by GSE2-1 (Fig. 6A).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 6.   GSE2-1-mediated activation of NF-kappa B is sensitive to wortmannin and depends on growth factors, suggesting involvement of Akt. A, NIH3T3 cells were transfected with the indicated plasmids and incubated overnight in serum-free medium followed by addition of 10% fetal serum. Wortmannin (100 nM) added 30 min before serum suppressed activation of NF-kappa B with both serum and GSE2-1. B, expression of GSE2-1 does not protect Akt phosphorylation from inhibitory activity of wortmannin in 293 cells. The results of Western immunoblotting with anti-human phospho-Akt (pAkt) antibodies were as follows. Protein extract from 293 cells are shown transfected with: insert-free vector, cells maintained in serum-free medium, column 1; insert-free vector after 30 min in 10% fetal serum, column 2; GSE2-1-expressing vector after 30 min in 10% fetal serum, column 3; GSE2-1-expressing vector, cells treated for 30 min with wortmannin (100 nM) before addition of serum, column 4; insert-free vector, cells treated for 30 min with 0.01 ng of TNF in 10% fetal serum, column 5. Notice that only 60-70% of 293 cells were transfected with GSE2-1-expressing vector. The amounts of pAkt were quantitated and normalized to the amount of actin.

The inhibition of PI3K activity suppresses phosphorylation of Akt (26). We analyzed the ability of GSE2-1 to regulate phosphorylation of Akt using antibodies specific to the phosphorylated form of Akt. In 293 cells growing in serum-free medium overnight, the medium was changed to serum-free every 30 min 4 times before protein extraction to avoid contamination with 293 cells-secreted factors. The treatment of these cells with 10% fetal serum for 30 min significantly increased Akt phosphorylation (Fig. 6B). The GSE2-1 transiently transfected cells (60 to 70% of cells were transfected) in fetal serum containing medium showed additional increase of Akt phosphorylation. Treatment of the cells with TNF had an effect on Akt phosphorylation similar to GSE2-1 expression (Fig. 6B). Expression of GSE2-1 did not protect Akt phosphorylation from the inhibitory activity of wortmannin (Fig. 6B).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In our search for GSEs protecting cells against TNF-induced apoptosis, we isolated a genetic element encoding the cytoplasmic part of an already known protein, SHPS-1/SIRPalpha . The isolated GSE protected cells from TNF and strongly induced transcriptional activity of NF-kappa B in a PI3K/Akt-dependent manner. Because NF-kappa B is known to protect cells from TNF, GSE-mediated activation of this transcription factor is presumably responsible for the inhibition of TNF-mediated apoptosis. Full-length SHPS-1/SIRPalpha shows effects opposite to those of the isolated GSE, suggesting that the GSE-encoded truncated form of this protein acts through a dominant negative mechanism, interfering with the function of the full-length protein.

What is the mechanism linking SHPS-1/SIRPalpha to NF-kappa B? The PI3K/Akt pathway is important for NF-kappa B activation by TNF (26, 28). Activated Akt phosphorylates the IKKbeta complex, which phosphorylates NF-kappa B inhibitor Ikappa B and stimulates its degradation (29), which leads to a release of NF-kappa B that accumulates in the nucleus and activates transcription of the target genes. The functional connection of SIRPalpha with the PI3K/Akt pathway was shown. Overexpression of SIRPalpha , but not of its tyrosineless mutant form, inhibits PI3K activation and stimulation of proliferation by growth factors (13, 22). On the contrary, ectopic expression of the cytoplasmic portion of SHPS1/SIRPalpha stimulates growth factor-dependent Akt phosphorylation. NF-kappa B activation seems to be the result of this effect because it was completely suppressed by the PI3K inhibitor wortmannin. Importantly, this effect of the GSE-encoded truncated protein was also dependent on the presence of tyrosine residues. These observations are consistent with the hypothetical model that the truncated dominant negative form of SHPS1/SIRPalpha competes with the full-length membrane-bound protein for some factors that are bound to these proteins in a tyrosine phosphorylation-dependent manner. There are two proteins belonging to the same family that are known to bind with SHPS1/SIRPalpha and mediate its biological functions, tyrosine phosphatases SHP-1 and -2 (15). SHPS1/SIRPalpha can bind both proteins when its own tyrosine residues in ITIM signals are phosphorylated with Src (13, 14, 22).

SHP-1 and -2 are involved in many pathways, the function of which requires tyrosine phosphorylation (30-32), including NF-kappa B signaling (16, 33). Despite significant homology between SHP-1 and -2, these proteins have opposite effects on cell viability. SHP-1 is pro-apoptotic and can suppress cell growth (34-37), and its absence stimulates NF-kappa B activation by TNF (33). In contrast, SHP-2 has an anti-apoptotic effect (38), stimulating Akt activation by growth factors (16, 39); its absence inhibits NF-kappa B activation by TNF (16). NF-kappa B activity is increased in cells from the Mev strain of mice deficient in SHP-1 (33). The opposite biological effect is associated with SHP-2 gene deficiency (16).

SHP-1 is linked to NF-kappa B through modulation of PI3K/Akt signaling. It causes dephosphorylation of tyrosine 688 inside the N-terminal SH2 domain of the regulatory subunit of PI3K p85 that turns it into an inhibitor of the catalytic subunit p110 (40, 41). The depletion of SHP-1 by the GSE-encoded cytoplasmic portion of SHPS-1/SIRPalpha might lead to the activation of the p110 subunit of PI3K and phosphorylation of Akt. Thus, dephosphorylation of the p85 regulatory subunit of PI3K might be one of the mechanisms through which dominant negative SHPS-1/SIRPalpha could activate NF-kappa B and promote TNF resistance. However, in our experiments GSE2 caused only a slight increase in the level of Akt phosphorylation in 293 cells, making it unlikely that this effect is solely responsible for the dramatic activation of NF-kappa B-dependent transcription. There could be additional targets for GSE2 downstream of Akt that remain to be identified.

Although the function of SHP-1 is consistent with the observed biological effects, the role of SHP-2 in our model remains less defined. There are contradictory reports on the activity of this phosphatase. There is evidence indicating that inactivation of SHP-2 decreases the transactivating abilities of NF-kappa B in response to interleukin 1 (16). At the same time, other reports claim that inactivation of SHP-2 increases the PI3K-dependent Akt activation with EGF (42) and that cooperation of SIRPalpha and SHP-2 had a negative effect on EGF-specific activation of PI3K (22). According to these data, the functions of the two phosphatases are similar and titration of SHP-2 by GSE2 could also stimulate EGF/PI3K-dependent activation of NF-kappa B. This apparent controversy has to be resolved in future experiments.

In summary, the biological effects of full-length SHPS-1/SIRPalpha can be explained through its ability to bind and compartmentalize SHP-1, and possibly SHP-2, with growth factor receptors causing their inactivation. We hypothesize that GSE-encoded proteins act as scavengers of SHP-1 and -2 in the cell, affecting proper targeting of these phosphatases to plasma membrane and thereby interfering with their inhibitory activity against growth factor-mediated signaling.

    FOOTNOTES

* This work was supported by a grant from Quark Biotech, Inc. (to N. N. and A. V. G.) and by National Insitutes of Health Grant CA60730 to (A. V. G.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Dept. of Virology, Lerner Research Inst., Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195. Tel.: 216-444-1058; Fax: 216-444-2998; E-mail: neznann@ccf.org.

Published, JBC Papers in Press, November 24, 2002, DOI 10.1074/jbc.M210698200

    ABBREVIATIONS

The abbreviations used are: TNF, tumor necrosis factor; PI3K, phosphoinositide 3-kinase; GSE, genetic suppressor elements; RT, reverse transcription; CHI, cycloheximide; SIRPalpha , signal regulatory protein alpha ; EGF, epidermal growth factor; ITIM, immunoreceptor tyrosine-based inhibitory motif.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Liu, Z. G., and Han, J. (2001) Curr. Issues Mol. Biol. 4, 79-90
2. Petak, I., and Houghton, J. A. (2001) Pathol. Oncol. Res. 7, 95-106[Medline] [Order article via Infotrieve]
3. Ashkenazi, A. (2002) Nat. Rev. Cancer 2, 420-430[CrossRef][Medline] [Order article via Infotrieve]
4. Baud, V., and Karin, M. (2001) Trends Cell Biol. 11, 372-377[CrossRef][Medline] [Order article via Infotrieve]
5. Cantley, L. C. (2002) Science 296, 1655-1657[Abstract/Free Full Text]
6. Lawlor, M. A., and Alessi, D. R. (2001) J. Cell Sci. 114, 2903-2910[Abstract/Free Full Text]
7. Karin, M., Cao, Y., Greten, F. R., and Li, Z. W. (2002) Nat. Rev. Cancer 2, 301-310[CrossRef][Medline] [Order article via Infotrieve]
8. Gudkov, A. V., Kazarov, A. R., Thimmapaya, R., Axenovich, S. A., Mazo, I. A., and Roninson, I. B. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3744-3748[Abstract]
9. Gudkov, A. V., and Roninson, I. B. (1997) Methods Mol. Biol. 69, 221-240[Medline] [Order article via Infotrieve]
10. Garkavtsev, I., Kazarov, A., Gudkov, A., and Riabowol, K. (1996) Nat. Genet. 14, 415-420[Medline] [Order article via Infotrieve]
11. Sanz, G., Mir, L., and Jacquemin-Sablon, A. (2002) Cancer Res. 62, 4453-4458[Abstract/Free Full Text]
12. Erez, N., Milyavsky, M., Goldfinger, N., Peles, E., Gudkov, A. V., and Rotter, V. (2002) Oncogene 2, 6713-6721[CrossRef]
13. Kharitonenkov, A., Chen, Z., Sures, I., Wang, H., Schilling, J., and Ullrich, A. (1997) Nature 386, 181-186[CrossRef][Medline] [Order article via Infotrieve]
14. Veillette, A., Thibaudeau, E., and Latour, S. (1998) J. Biol. Chem. 273, 22719-22728[Abstract/Free Full Text]
15. Sharenberg, A. M., and Kinet, J.-P. (1996) Cell 87, 961-964[Medline] [Order article via Infotrieve]
16. You, M., Flick, L. M., Yu, D., and Feng, G. S. (2001) J. Exp. Med. 193, 101-110[Abstract/Free Full Text]
17. Markowitz, D., Goff, S., and Bank, A. (1988) Virology 167, 400-406[Medline] [Order article via Infotrieve]
18. Miller, A. D., and Rosman, G. J. (1989) BioTechniques 7, 980-986[Medline] [Order article via Infotrieve]
19. Miagkov, A. V., Kovalenko, D. V., Brown, C. E., Didsbury, J. R., Cogswell, J. P., Stimpson, S. A., Baldwin, A. S., and Makarov, S. S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 13859-13864[Abstract/Free Full Text]
20. Foos, G., Garcia-Ramirez, J. J., Galang, C. K., and Hauser, C. A. (1998) J. Biol. Chem. 273, 18871-18880[Abstract/Free Full Text]
21. Paya, C. V., Ten, R. M., Bessia, C., Alcami, J., Hay, R. T., and Virelizier, J. L. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7826-7830[Abstract]
22. Wu, C. J., Chen, Z., Ullrich, A., Greene, M. I., and O'Rourke, D. M. (2000) Oncogene 19, 3999-4010[CrossRef][Medline] [Order article via Infotrieve]
23. Takada, T., Matozaki, T., Takeda, H., Fukunaga, K., Noguchi, T., Fujioka, Y., Okazaki, I., Tsuda, M., Yamao, T., Ochi, F., and Kasuga, M. (1998) J. Biol. Chem. 273, 9234-9242[Abstract/Free Full Text]
24. Georganas, C., Liu, H., Perlman, H., Hoffmann, A., Thimmapaya, B., and Pope, R. M. (2000) J. Immunol. 165, 7199-7206[Abstract/Free Full Text]
25. Van Antwerp, D. J., Martin, S. J., Verma, I. M., and Green, D. R. (1998) Trends Cell Biol. 8, 107-111[CrossRef][Medline] [Order article via Infotrieve]
26. Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., and Donner, D. B. (1999) Nature 401, 82-85[CrossRef][Medline] [Order article via Infotrieve]
27. Romashkova, J. A., and Makarov, S. S. (1999) Nature 401, 86-90[CrossRef][Medline] [Order article via Infotrieve]
28. Gustin, J. A., Maehama, T., Dixon, J. E., and Donner, D. B. (2001) J. Biol. Chem. 276, 27740-27744[Abstract/Free Full Text]
29. Karin, M., and Ben-Neriah, Y. (2000) Annu. Rev. Immunol. 18, 621-663[CrossRef][Medline] [Order article via Infotrieve]
30. Cambier, J. C. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 5993-5995[Free Full Text]
31. Maile, L. A., and Clemmons, D. R. (2002) J. Biol. Chem. 277, 8955-8960[Abstract/Free Full Text]
32. Stofega, M. R., Argetsinger, L. S., Wang, H., Ullrich, A., and Carter-Su, C. (2000) J. Biol. Chem. 275, 28222-28229[Abstract/Free Full Text]
33. Massa, P. T., and Wu, C. (1998) J. Interferon Cytokine Res. 18, 499-507[Medline] [Order article via Infotrieve]
34. Thangaraju, M., Sharma, K., Leber, B., Andrews, D. W., Shen, S. H., and Srikant, C. B. (1999) J. Biol. Chem. 274, 29549-29557[Abstract/Free Full Text]
35. Hsu, H. C., Shultz, L. D., Su, X., Shi, J., Yang, P. A., Relyea, M. J., Zhang, H. G., and Mountz, J. D. (2001) J. Immunol. 166, 772-780[Abstract/Free Full Text]
36. Migone, T. S., Cacalano, N. A., Taylor, N., Yi, T., Waldmann, T. A., and Johnston, J. A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 3845-3850[Abstract/Free Full Text]
37. Daigle, I., Yousefi, S., Colonna, M., Green, D. R., and Simon, H. U. (2002) Nat. Med. 8, 61-67[CrossRef][Medline] [Order article via Infotrieve]
38. Hideshima, T., Nakamura, N., Chauhan, D., and Anderson, K. C. (2001) Oncogene 20, 5991-6000[CrossRef][Medline] [Order article via Infotrieve]
39. Wu, C. J., O'Rourke, D. M., Feng, G. S., Johnson, G. R., Wang, Q., and Greene, M. I. (2001) Oncogene 20, 6018-6025[CrossRef][Medline] [Order article via Infotrieve]
40. Cuevas, B. D., Lu, Y., Mao, M., Zhang, J., LaPushin, R., Siminovitch, K., and Mills, G. B. (2001) J. Biol. Chem. 276, 27455-27461[Abstract/Free Full Text]
41. Cuevas, B., Lu, Y., Watt, S., Kumar, R., Zhang, J., Siminovitch, K. A., and Mills, G. B. (1999) J. Biol. Chem. 274, 27583-27589[Abstract/Free Full Text]
42. Zhang, S. Q., Tsiaras, W. G., Araki, T., Wen, G., Minichiello, L., Klein, R., and Neel, B. G. (2002) Mol. Cell. Biol. 22, 4062-4072[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.